Abstract
Liquid biopsy is a promising clinical tool that can provide critical information for prognostication and which may inform treatment decisions in men with metastatic castration-resistant prostate cancer. Here we discuss the Foundation Medicine plasma cell-free circulating tumor DNA assay, its pros and cons, and potential clinical utility.See related article by Tukachinsky et al., p. 3094.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical cancer research : an official journal of the American Association for Cancer Research
Paper Title
Journal
Date
